Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xilio PSMA-targeted masked T cell engager
- Development stage
- Preclinical
- Lead developer
- Xilio Therapeutics
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Xilio PSMA-targeted masked T cell engager is a preclinical biologic being developed by Xilio Therapeutics for the treatment of prostate cancer. Utilizing Xilio's proprietary Advanced Tumor-Activated Cell Engager (ATACR) platform, the drug is designed as a bispecific molecule that simultaneously binds to prostate-specific membrane antigen (PSMA) on tumor cells and the CD3 component of the T cell receptor complex. A key feature of the ATACR format is the inclusion of a mask on the CD3-targeting domain, which prevents systemic T cell activation and associated toxicities, such as cytokine release syndrome. This mask is engineered to be cleaved by proteases specifically found within the tumor microenvironment, thereby restricting potent T cell-mediated cytotoxicity to the tumor site and improving the therapeutic index. Xilio nominated a development candidate for this program in the third quarter of 2025 and plans to submit an Investigational New Drug (IND) application in the first quarter of 2027.
- Other names
- PSMA-targeted ATACRPSMA-masked T cell engagerPSMA-Xilio-PSMA-masked T cell engager-T cell engagerPSMA
02
Targets
CD3 (T-cell surface glycoprotein CD3)PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on Xilio PSMA-targeted masked T cell engager.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Xilio PSMA-targeted masked T cell engager.